Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa

Simple item page
dc.contributor.authorDheda, Keertanen_ZA
dc.contributor.authorTheron, Granten_ZA
dc.contributor.authorWelte, Alexen_ZA
dc.date.accessioned2017-09-07T13:56:06Z
dc.date.available2017-09-07T13:56:06Z
dc.date.issued2014-10
dc.descriptionCITATION: Dheda, K., Theron, G. & Welte, A. 2014. Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. Lancet Global Health, 2(10):e554–e556, doi:10.1016/S2214-109X(14)70305-5.
dc.descriptionThe original publication is available at http://www.thelancet.com/journals/langlo
dc.description.abstractThe Xpert MTB/RIF assay is an accurate test for the diagnosis of tuberculosis when an adequate sputum sample can be obtained; even in smear-negative tuberculosis the sensitivity is about 67%.1, 2 Although the assay turnaround time is under 2 h, depending on the health-care setting, time to tuberculosis treatment can be 2 weeks or more in a substantial number of patients.3 The technology has now been endorsed by WHO as a frontline test for tuberculosis in populations where there is a high incidence of HIV.4 Indeed, several countries in Africa are rolling out Xpert MTB/RIF.5 However, for expanded and sustained uptake, governments and policy makers require information about the cost-effectiveness of the technology to allow for appropriate planning and allocation of health-care resources. Cost-effectiveness must be balanced against affordability and sustainability. Thus, although the diagnostic accuracy of the technique is not in doubt, questions remain about the cost-effectiveness of the technology given that the overall number of patients treated for tuberculosis can remain unchanged6 and given the high rates of empirical treatment in resource-poor health-care settings.7en_ZA
dc.description.urihttp://www.thelancet.com/journals/langlo/article/PIIS2214-109X(14)70305-5/fulltext
dc.description.versionPublisher's version
dc.format.extent3 pages
dc.identifier.citationDheda, K., Theron, G. & Welte, A. 2014. Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. Lancet Global Health, 2(10):e554–e556, doi:10.1016/S2214-109X(14)70305-5.
dc.identifier.issn2214-109X (online)
dc.identifier.otherdoi:10.1016/S2214-109X(14)70305-5
dc.identifier.urihttp://hdl.handle.net/10019.1/102207
dc.language.isoen_ZAen_ZA
dc.publisherElsevier
dc.rights.holderAuthors retain copyright
dc.subjectTuberculosis -- Diagnosis -- South Africaen_ZA
dc.subjectXpert MTB/RIF -- Cost effectivenessen_ZA
dc.titleCost-effectiveness of Xpert MTB/RIF and investing in health care in Africaen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
dheda_costeffectiveness_2014.pdf
Size:
41.33 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles ((SACEMA) South African Centre for Epidemiological Modelling and Analysis )